Amyloid-beta clearance
AssigneeGwangju Institute of Science and Technology
InventorsWoo Jin Park, Hye-eun Han
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating an amyloid β-caused disease, which comprises as an active ingredient a NIa (nuclear inclusion a) protease or a gene carrier containing a nucleotide sequence encoding the NIa protease. The pharmaceutical composition of this invention is very effective to treat a variety of diseases or disorders, inter alia, Alzheimer's disease.
Claims9
A method for treating an amyloid β-caused disease, which comprises administering to a mammalian subject a pharmaceutical composition comprising as an active ingredient an isolated or synthesized nuclear inclusion a NIa protease of Turnip mosaic virus (TuMV) consisting of the amino acid sequence of SEQ ID NO:1 or a gene carrier containing a nucleotide sequence encoding the NIa protease of TuMV,
- wherein the gene carrier is (i) a naked recombinant DNA molecule, (ii) a plasmid, (iii) a viral vector selected from the group consisting of adenovirus, adeno-associated virus, retrovirus, lentivirus, herpes simplex virus and vaccinia virus, or (iv) a liposome or a niosome containing a naked recombinant DNA molecule and a plasmid;
- and
- wherein the NIa protease cleaves intracellular or extracellular amyloid β.
Dependencies are inferred from the claim text.